Design Therapeutics downgraded by SVB Securities with a new price target
$DSGN
Biotechnology: Pharmaceutical Preparations
Health Care
SVB Securities downgraded Design Therapeutics from Outperform to Market Perform and set a new price target of $6.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2024 | $6.00 → $12.00 | Neutral → Overweight | Piper Sandler |
| 11/14/2023 | $42.00 → $6.00 | Overweight → Neutral | Piper Sandler |
| 8/15/2023 | $19.00 → $6.00 | Outperform → Neutral | Wedbush |
| 8/15/2023 | $23.00 → $7.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 8/15/2023 | $6.00 | Outperform → Market Perform | SVB Securities |
| 5/4/2023 | $6.00 | Sell → Neutral | Goldman |
| 6/10/2022 | $21.00 | Outperform | Wedbush |
| 5/2/2022 | $30.00 | Outperform | RBC Capital Mkts |
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
3 - Design Therapeutics, Inc. (0001807120) (Issuer)
3 - Design Therapeutics, Inc. (0001807120) (Issuer)
Piper Sandler upgraded Design Therapeutics from Neutral to Overweight and set a new price target of $12.00 from $6.00 previously
Piper Sandler downgraded Design Therapeutics from Overweight to Neutral and set a new price target of $6.00 from $42.00 previously
Wedbush downgraded Design Therapeutics from Outperform to Neutral and set a new price target of $6.00 from $19.00 previously
SC 13D/A - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
EFFECT - Design Therapeutics, Inc. (0001807120) (Filer)
S-3 - Design Therapeutics, Inc. (0001807120) (Filer)
10-Q - Design Therapeutics, Inc. (0001807120) (Filer)
CARLSBAD, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present during the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 p.m. ET in New York. A live webcast of the presentation will be available here and in the investors section of the company's website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on
CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company's website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new cla
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations Through up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress across its portfolio of GeneTAC® candidates and reported financial results for the first quarter 2025. "Design continued its progress throug
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) with Phase 1 Development to Start in 2024; Observational Study Underway to Confirm Patient Characteristics and Evaluate Potential Endpoints New Program Unveiled for Huntington's Disease (HD) Targeting Reduction of Mutant Huntingtin with a GeneTAC™ Small Molecule Cash and Securities of $281.8 Million at Year-end 2023 Support Five-Year Operating Runway and Advancement of Up to Four Progra
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update. The event will be webcast live under the "Events" section of the Investors page of www.designtx.com and can also be accessed here. A replay of the webcast will be archived on the Design website for 30 days. Dial-in information for conference participants may be obtained by regi
DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation Composition Design Plans to Proceed with an Improved DT-216 Formulation and Initiate a Multiple Dose Phase 1 Clinical Study in the Second Half of 2024 Conference Call and Webcast to be Held Today at 4:30pm ET CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported initial results from the company's Phase 1 multiple-ascending dose (MAD) clinical
CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, M.D., as Chief Medical Officer (CMO). Dr. Storgard brings over two decades of leadership and hands-on drug development experience, having successfully advanced multiple assets from preclinical stages through global regulatory approvals. "We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC® small molecules toward key clinical milestones," said Pratik Shah, Ph.D., chairperson an
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ
Phase 1 Trial of DT-216, a Novel FA GeneTAC™ Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel GeneTAC™ Small Molecules for the Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) to be Presented at ARVO 2022 Well-Capitalized with $384.1 Million in Cash and Investments at the End of 2021 to Support Upcoming Milestones CARLSBAD, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced pipeline and business progress and reported fourth quarter and full year 2021 financial results. "This is an e